axitinib | Cancer Search

Details 19 Trials 3 Therapies

An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.

codes

FDA: C9LVQ0YUXG

NCIt: C38718

synonyms

Inlyta

AG-013736

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

145 sites for NCT04510597

Renal Cell Carcinoma

avelumab, +4 more drugs

immunotherapy, +2 more types

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

50 sites for NCT04540705

Clear Cell Renal Cell Carcinoma

axitinib, +3 more drugs

immunotherapy, +2 more types

Axitinib + Ipilimumab in Advanced Melanoma

1 site for NCT04996823

Melanoma

axitinib, +1 more drug

immunotherapy, +1 more type

A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer

41 sites for NCT04585815